Cardiol Therapeutics (TSE:CRDL) Stock Price Down 14.6% – Here’s Why

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) traded down 14.6% during mid-day trading on Monday . The stock traded as low as C$1.24 and last traded at C$1.29. 551,069 shares traded hands during mid-day trading, an increase of 405% from the average session volume of 109,045 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Price Performance

The company has a 50-day moving average of C$1.50 and a 200-day moving average of C$1.65. The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49. The stock has a market cap of C$129.00 million, a price-to-earnings ratio of -3.15 and a beta of 1.31.

Cardiol Therapeutics (TSE:CRDL) last posted its quarterly earnings data on Thursday, November 13th. The company reported C($0.12) earnings per share for the quarter. As a group, equities research analysts predict that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.